Propanc Biopharma
PPCB
4 hedge funds and large institutions have $69.5K invested in Propanc Biopharma in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
100% more funds holding
Funds holding: 2 → 4 (+2)
0% more ownership
Funds ownership: 0.04% → 0.04% (+0%)
64% less capital invested
Capital invested by funds: $191K → $69.5K (-$121K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$28.2K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$24.5K |
| 3 |
Two Sigma Investments
New York
|
+$18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$71K |
| 2 |
MG
Marex Group
London,
|
-$5.98K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MG
1
Marex Group
London,
| $35.1K | -$5.98K | -216 | -8% |
|
|
TSS
2
Two Sigma Securities
New York
| $13.7K | +$28.2K | +1,019 | New |
|
|
XT
3
XTX Topco
George Town,
Cayman Islands
| $11.9K | +$24.5K | +885 | New |
|
|
4
Two Sigma Investments
New York
| $8.72K | +$18K | +650 | New |
|
5
Morgan Stanley
New York
| $1 | – | – | – |
|
|
VF
6
Virtu Financial
New York
| – | -$71K | -1,667 | Closed |
|
PPCB Hedge Fund Activity: Q4 2025 in Review
4 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Propanc Biopharma (PPCB) for Q4 2025, worth a combined $69.5K — down 64% from $191K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new PPCB positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $28.2K. The largest seller was Virtu Financial, exiting entirely with an estimated $71K sold.
- 4 institutional investors held Propanc Biopharma (PPCB) as of Q4 2025, up from 2 in Q3 2025.
- Funds reported $69.5K of Propanc Biopharma stock for Q4 2025, down 64% quarter-over-quarter.
- 3 funds opened new Propanc Biopharma positions in Q4 2025 and 1 closed out, a net change of +2 holders.
- The largest Propanc Biopharma buyer in Q4 2025 was Two Sigma Securities, an estimated $28.2K added.
- The largest Propanc Biopharma seller in Q4 2025 was Virtu Financial, an estimated $71K sold.
Based on aggregated 13F filings for Q4 2025.